Innovation & exploitation
A key goal and strength of ITM is surrounded by technology transfer experts to ensure the exploitation of our innovation and clinical translation of our research.
We are working with SATT Conectus, the organization for accelerating technology transfer in the Alsace region, and actively interact with local start-up incubators SEMIA (Strasbourg) and Baselaunch (Basel region) to commercialize our therapeutic compounds and disagnostic tools. Furthermore, the ITM is an active member and partner of Alsace Biovalley, a French world-class biocluster dedicated to therapeutic innovations.
In 2019, Prof. Baumert founded the biotech company Alentis Therapeutics to commercialize and clinically develop Claudin-1 specific monoclonal antibodies, discovered in his laboratory. The antibodies are now in several phase 1 and 2 clinical trials to treat fibrosis and cancer as single agent and in combination therapy.
ITM scientists and clinicians actively collaborate with pharma in preclinical and clinical programs.